[The treatment of multi-drug resistant tuberculosis in the Clinic for Pulmonary Diseases "Podhrastovi" Sarajevo].
One of the greatest problems in the treatment of the tuberculosis is the treatment of drug-resistant cases. In particular, the treatment of patients with multi-drug resistance (MDR) i.e. resistance to at least isonisid and rifampicin, is long and costly, and reqiures the use of drugs which frequently cause severe, often toxic, reactions. Multi-drug resistance causes a great concern among tuberculosis experts and public health officials. The development of multi-drug resistance in high levels is a sign that a control strategies are failing. MDR-TB may become an obstacle to effective treatment of tuberculosis. TB patients with MDR strains requires individualized approach and expensive treatment in specialised units. Treatment outcome for MDR tuberculosis (MDR-TB) is often poor with low cure rates and increased fatality rates, these patients may go on infecting others in the community because they remain infectious for a prolonged period of time. Since drug-resistance develops because of inadequate use of drugs, the qualitative treatment of new cases of tuberculosis is a key element of tuberculosis control because effective treatment quickly renders the patient non contagious and therefore stops the transmission of illness. In the Federation B&H the DOTS (Direct Observed Short Course of Therapy) recommended by WHO has been in use from 1994. Although we had some multi-drug resistant cases but in very small number. Using new regimen of treatment which is long lasting and very expensive we succeeded to cure them. In this article we show the results of the treatment of these patients in three-year period (2001-2003) in the Clinic for Pulmonary Diseases and tuberculosis "Podhrastovi" Sarajevo.
Cukić
Vesna
V
Klinika za plućne bolesti i tuberkulozu Podhrastovi, Klinickogt centra Univerziteta u Sarajevu, Bosna i Hercegovina.
Maglajlić
Jasminka
J
Dizdarević
Zehra
Z
Zvizić
Sukrija
S
Zutić
Hasan
H
D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*